Angiosarcoma Clinical Trials 2023

What are the top hospitals conducting angiosarcoma research?

In the realm of medical advancements, clinical trials play a crucial role in uncovering new treatments for rare and challenging conditions like angiosarcoma. In Houston, Texas, M D Anderson Cancer Center leads the charge with two active angiosarcoma trials and an impressive total of seven conducted studies since their first recorded trial in 2007. The University of Colorado in Aurora is also making strides with two ongoing clinical trials dedicated to this aggressive cancer type. Though they may have a smaller number of all-time trials at just two, their commitment to research since recording their initial angiosarcoma trial in 2010 showcases promising efforts.

Meanwhile, on the East Coast, Columbia University Medical Center in New york stands tall with its own contributions to angiosarcoma research. With two active clinical trials and three completed studies under their belt since initiating their first trial back in 2007, they are making significant headway against this challenging disease.

Additionally worth mentioning are Memorial Sloan Kettering's satellite facilities: Basking Ridge and Monmouth locations. While these sites have limited protocol activities compared to their flagship institution, they too recognize the importance of investigating new approaches for treating angiosarcoma. Both centers currently have one active clinical trial each and share the distinction of being pioneers by recording their inaugural angiosarcoma trials as recently as 2023.

The dedication shown by these leading hospitals not only sheds light on the complexity of combating angiosarcoma but also offers hope for patients facing this rare condition. Through continued research and innovative approaches explored within these clinical trials, we inch closer towards improving outcomes and ultimately finding a cure that could transform lives affected by this aggressive cancer type

Which are the best cities for angiosarcoma clinical trials?

When it comes to angiosarcoma clinical trials, several cities emerge as key hubs for research and treatment. Los Angeles, California stands out with 8 active trials focusing on promising interventions like Nivolumab, Botensilimab, and Trilaciclib with or without trastuzumab + pertuzumab. Anchorage, Alaska also offers 8 ongoing studies primarily investigating Nivolumab among other potential treatments. New york, New York follows closely behind with 5 active trials exploring interventions such as Botensilimab and Trilaciclib with or without trastuzumab + pertuzumab. Additionally, Sacramento, California contributes to the field of angiosarcoma research with 4 active trials centered around Nivolumab and various other approaches. Finally, Houston, Texas engages in this crucial work through its participation in 3 active trials studying Dose Escalation/Deescalation strategies along with Sintilimab and Botensilimab utilization. These cities serve as vital centers for advancing our understanding of angiosarcoma treatments through clinical trials that offer hope for improved outcomes.

Which are the top treatments for angiosarcoma being explored in clinical trials?

In the realm of angiosarcoma research, several treatments have emerged as frontrunners in ongoing clinical trials. Sintilimab, a novel therapy introduced in 2021, is currently being explored in one active trial specifically targeting angiosarcoma. Another promising contender is paclitaxel, with six all-time trials dedicated to addressing this challenging cancer since its debut in 2010. Additionally, botensilimab has also shown potential for combating angiosarcoma and is currently under investigation in one active trial after its introduction to the medical world in 2019. These exciting developments signify significant progress towards effective treatments for patients fighting against angiosarcoma.

What are the most recent clinical trials for angiosarcoma?

Recent clinical trials have brought promising advancements in the field of angiosarcoma treatment. Notably, a phase 1 dose escalation group study has become available, exploring new dosage levels for improved outcomes in patients with this rare cancer. Another noteworthy trial involves Sintilimab, a novel therapy being investigated in phase 2 studies to determine its efficacy and safety profile specifically for angiosarcoma. Additionally, paclitaxel has undergone both phase 1 and phase 2 trials as a potential treatment option for angiosarcoma since May 2019. Other ongoing trials include botensilimab (phase 1) and eribulin (phase 2), which could potentially offer alternative therapeutic options for individuals battling this challenging disease.

What angiosarcoma clinical trials were recently completed?

Several significant clinical trials investigating potential treatments for angiosarcoma have recently reached completion. In December 2018, Athenex, Inc. successfully concluded a trial evaluating the efficacy of Oraxol. Furthermore, in March 2017, the OHSU Knight Cancer Institute wrapped up a pharmacological study aimed at advancing our understanding and management of this challenging disease. Lastly, Washington University School of Medicine completed a trial exploring the potential benefits of Dexrazoxane in February 2016. These trials represent important steps forward in the pursuit of improved therapies for angiosarcoma patients and highlight ongoing efforts to combat this rare form of cancer.